As mentioned, one concern with the use of CDK4/6 inhibitors is the development of resistance mechanisms to these therapies through quasi-redundant or alternative signaling pathways, which has been reported in breast cancer and medulloblastoma patients receiving CDK inhibitor monotherapy (12). This evidence concerns the gene CDK4 and medulloblastoma.